Cited by 545Hemoglobinopathies and Related DisordersBlood transfusion and managementAcute Ischemic Stroke Management

Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia

Open access
DeBaun, Michael R., Gordon, Mae, McKinstry, Robert C., Noetzel, Michael J., White, Desiree A., Sarnaik, Sharada A., Meier, Emily R., Howard, Thomas H. +30 more·2014·New England Journal of Medicine

Abstract

BACKGROUND: Silent cerebral infarcts are the most common neurologic injury in children with sickle cell anemia and are associated with the recurrence of an infarct (stroke or silent cerebral infarct). We tested the hypothesis that the incidence of the recurrence of an infarct would be lower among children who underwent regular blood-transfusion therapy than among those who received standard care. METHODS: In this randomized, single-blind clinical trial, we randomly assigned children with sickle cell anemia to receive regular blood transfusions (transfusion group) or standard care (observation group). Participants were between 5 and 15 years of age, with no history of stroke and with one or more silent cerebral infarcts on magnetic resonance imaging and a neurologic examination showing no abnormalities corresponding to these lesions. The primary end point was the recurrence of an infarct, defined as a stroke or a new or enlarged silent cerebral infarct. RESULTS: A total of 196 children (mean age, 10 years) were randomly assigned to the observation or transfusion group and were followed for a median of 3 years. In the transfusion group, 6 of 99 children (6%) had an end-point event (1 had a stroke, and 5 had new or enlarged silent cerebral infarcts). In the observation group, 14 of 97 children (14%) had an end-point event (7 had strokes, and 7 had new or enlarged silent cerebral infarcts). The incidence of the primary end point in the transfusion and observation groups was 2.0 and 4.8 events, respectively, per 100 years at risk, corresponding to an incidence rate ratio of 0.41 (95% confidence interval, 0.12 to 0.99; P=0.04). CONCLUSIONS: Regular blood-transfusion therapy significantly reduced the incidence of the recurrence of cerebral infarct in children with sickle cell anemia. (Funded by the National Institute of Neurological Disorders and Stroke and others; Silent Cerebral Infarct Multi-Center Clinical Trial ClinicalTrials.gov number, NCT00072761, and Current Controlled Trials number, ISRCTN52713285.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1401731

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the SIT trial, without transfusion, silent cerebral infarct burden at baseline predicts further accrual of ischemic lesions and stroke.

    “the Silent Infarct Transfusion (SIT) trial has shown that, without transfusion, SCI burden at baseline predicts further accrual of ischemic lesions and stroke (172)”

    From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [172]

    The Results (Neurologic Outcomes; page unavailable) report new or enlarged infarcts and strokes in the observation group, supporting recurrence without transfusion. But the reported baseline factors associated with recurrence are younger age, recurring headaches, and higher reticulocyte count; the paper does not report that baseline silent cerebral infarct burden predicts those outcomes. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • In children with sickle cell disease, the SIT trial showed that transfusion may reduce incident silent cerebral infarcts, although SCIs were part of a composite endpoint including stroke, hampering analysis of the effect on SCI alone.

    “In children with SCD, the SIT trial has shown that transfusion may reduce incident SCI, although SCIs were part of a composite endpoint that also included stroke, thus hampering the analysis of the effect of transfusion on SCI alone (172).”

    From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [172]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
DeBaun, M. R., Gordon, M., McKinstry, R. C., Noetzel, M. J., White, D. A., Sarnaik, S. A., Meier, E. R., Howard, T. H., Majumdar, S., Inusa, B. P. D., Telfer, P. T., Kirby-Allen, M., McCavit, T. L., Kamdem, A., Airewele, G., Woods, G. M., Berman, B., Panepinto, J. A., Fuh, B. R., Kwiatkowski, J. L., King, A. A., Fixler, J. M., Rhodes, M. M., Thompson, A. A., Heiny, M. E., Redding-Lallinger, R. C., Kirkham, F. J., Dixon, N., Gonzalez, C. E., Kalinyak, K. A., Quinn, C. T., Strouse, J. J., Miller, J. P., Lehmann, H., Kraut, M. A., Ball, W. S., Hirtz, D., & Casella, J. F.
Affiliations
  • Children's National (US)
  • Wayne State University (US)
  • University of Alabama at Birmingham (US)
  • University of Mississippi Medical Center (US)
  • St Thomas' Hospital (GB)
  • Barts Health NHS Trust (GB)
  • University of Toronto (CA)
  • The University of Texas Southwestern Medical Center (US)
  • Hôpital Intercommunal de Créteil (FR)
  • Baylor College of Medicine (US)
  • University of Missouri–Kansas City (US)
  • Case Western Reserve University (US)
  • Cincinnati Children's Hospital Medical Center (US)
  • Children's Hospital of Philadelphia (US)
  • Sinai Hospital (US)
  • The Ohio State University (US)
  • Northwestern University (US)
  • Indiana University – Purdue University Indianapolis (US)
  • University College London (GB)
  • Georgetown University Medical Center (US)
  • Washington University in St. Louis (US)
  • Johns Hopkins University (US)
  • National Institutes of Health (US)
Venue
New England Journal of Medicine
Published
2014-08-21
Volume
371
Issue
8
Pages
699-710
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2095095757
Cited by
545
References
31
Citations by year
2026: 27 · 2025: 24 · 2024: 36 · 2023: 47 · 2022: 42 · 2021: 45 · 2020: 52 · 2019: 38 · 2018: 46 · 2017: 61 · 2016: 69 · 2015: 34 · 2014: 18 · 2013: 3
FWCI
30.44
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Eli Lilly and Company
  • Children's Hospital of Philadelphia (UL1TR000003)
  • Johns Hopkins University (UL1TR001079)
  • Institute of Clinical and Translational Sciences (UL1TR000448)
  • Shire
  • National Institutes of Health (UL1TR001079, UL1TR000448, UL1TR000003)
  • National Institute of Neurological Disorders and Stroke (U01NS042804)
  • National Center for Research Resources
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Genetics › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Biochemistry › Blood transfusion and management
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
Keywords
sickle cell disease, silent cerebral infarction, blood transfusion, transfusion therapy, stroke prevention, pediatric patients, neurologic injury
MeSH terms
Adolescent, Anemia, Sickle Cell, Blood Transfusion, Cerebral Infarction, Child, Child, Preschool, Female, Ferritins, Hemoglobin, Sickle, Humans, Intelligence, Male, Single-Blind Method, Secondary Prevention, Intention to Treat Analysis, Transfusion Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review